ABBOTT LABORATORIES Cash & Equivalents 2006-2026 | ABT
What is cash & equivalents?
Cash and cash equivalents can be defined as the most liquid assets on a company's balance sheet, including cash on hand and short-term investments maturing within 90 days.
What is ABBOTT LABORATORIES's current cash & equivalents?
ABBOTT LABORATORIES (ABT) annual cash & equivalents for 2025 was $8.52B, a 11.90% increase from 2024. ABBOTT LABORATORIES cash & equivalents for the quarter ending March 31, 2026 was $6.80B.
What was ABBOTT LABORATORIES's cash & equivalents in 2024?
ABBOTT LABORATORIES annual cash & equivalents for 2024 was $7.62B, a 10.44% increase from 2023.
What was ABBOTT LABORATORIES's cash & equivalents in 2023?
ABBOTT LABORATORIES annual cash & equivalents for 2023 was $6.90B, a 30.22% decline from 2022.
What is ABBOTT LABORATORIES's 5-year cash & equivalents CAGR?
ABBOTT LABORATORIES cash & equivalents grew at a compound annual growth rate (CAGR) of 4.50% from FY2020 to FY2025, going from $6.84B to $8.52B over 5 years.
Year-over-year comparison from 10-K annual reports
| Period | Value | Change | Source |
|---|---|---|---|
| FY2025 | $8.52B | +11.9% | 10-K |
| FY2024 | $7.62B | +10.4% | 10-K |
| FY2023 | $6.90B | -30.2% | 10-K |
| FY2022 | $9.88B | +0.8% | 10-K |
| FY2021 | $9.80B | +43.3% | 10-K |
| FY2020 | $6.84B | +77.2% | 10-K |
| FY2019 | $3.86B | +0.4% | 10-K |
| FY2018 | $3.84B | -59.1% | 10-K |
| FY2017 | $9.41B | -49.5% | 10-K |
| FY2016 | $18.62B | +272.3% | 10-K |
| FY2015 | $5.00B | +23.1% | 10-K |
| FY2014 | $4.06B | +16.9% | 10-K |
| FY2013 | $3.48B | -67.8% | 10-K |
| FY2012 | $10.80B | +58.5% | 10-K |
| FY2011 | $6.81B | +86.8% | 10-K |
| FY2010 | $3.65B | -58.6% | 10-K |
| FY2009 | $8.81B | +114.2% | 10-K |
| FY2008 | $4.11B | +67.4% | 10-K |
| FY2007 | $2.46B | +371.3% | 10-K |
| FY2006 | $521.2M | - | 10-K |